195 related articles for article (PubMed ID: 32044274)
1. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.
Melody M; Al Ali N; Zhang L; Ramadan H; Padron E; Sallman D; Sweet K; Lancet J; List A; Bennett JM; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):324-328. PubMed ID: 32044274
[TBL] [Abstract][Full Text] [Related]
2. Incorporating mutations and bone marrow fibrosis into the revised international prognostic scoring system in myelodysplastic syndromes.
Zhao Y; Guo J; Zhao S; Wang R; Wu D; Chang C
Leuk Lymphoma; 2024 Jan; 65(1):100-108. PubMed ID: 37865969
[TBL] [Abstract][Full Text] [Related]
3. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
Loghavi S; Al-Ibraheemi A; Zuo Z; Garcia-Manero G; Yabe M; Wang SA; Kantarjian HM; Yin CC; Miranda RN; Luthra R; Medeiros LJ; Bueso-Ramos CE; Khoury JD
Br J Haematol; 2015 Oct; 171(1):91-9. PubMed ID: 26123119
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.
Jain AG; Zhang L; Bennett JM; Komrokji R
Ann Lab Med; 2022 May; 42(3):299-305. PubMed ID: 34907099
[TBL] [Abstract][Full Text] [Related]
5. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.
Ramos F; Robledo C; Izquierdo-García FM; Suárez-Vilela D; Benito R; Fuertes M; Insunza A; Barragán E; Del Rey M; García-Ruiz de Morales JM; Tormo M; Salido E; Zamora L; Pedro C; Sánchez-Del-Real J; Díez-Campelo M; Del Cañizo C; Sanz GF; Hernández-Rivas JM;
Oncotarget; 2016 May; 7(21):30492-503. PubMed ID: 27127180
[TBL] [Abstract][Full Text] [Related]
7. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis.
Alvarez-Larrán A; López-Guerra M; Rozman M; Correa JG; Hernández-Boluda JC; Tormo M; Martínez D; Martín I; Colomer D; Esteve J; Cervantes F
Ann Hematol; 2019 Oct; 98(10):2319-2328. PubMed ID: 31396671
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and characteristics of patients with
Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
[TBL] [Abstract][Full Text] [Related]
12. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of mutations of 14 genes among 87 patients with myelodysplastic syndrome].
Zhou X; Jin H; Mu Q; Sheng L; Lai B; Zhu H; Ouyang G
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Oct; 36(10):953-956. PubMed ID: 31598934
[TBL] [Abstract][Full Text] [Related]
14. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
Jin J; Hu C; Yu M; Chen F; Ye L; Yin X; Zhuang Z; Tong H
PLoS One; 2014; 9(6):e100206. PubMed ID: 24936872
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
18. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
19. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
20. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
